BridgeMD
Evaluation of the safety and efficacy of Bevacizumab in patients with persistent respiratory disorders after COVID-19 infection
EU CTIS ID: 2024-520308-24-00
What this study is testing
To assess efficacy of bevacizumab injection in long COVID patients with impaired DLCO (<75% of predicted value) within 3 months after the first bevacizumab injection. The positive criteria will be a 10% increase in DLCO at three months after the introduction of bevacizumab.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1- Patients over 18 years ≤70 years
- 2- Social security affiliation
- 3- Good understanding of the French language
- 4- Written informed consent
- 5- Documented COVID-19 infection (PCR or CT scan) more than 3 months before inclusion
- 6- Long COVID suspicion with dyspnea (mMRC≥2 at inclusion)
You likely can't join if
- 1- Acute COVID-19 infection
- 22- Pregnant or breastfeeding women
- 23- Vulnerable populations (patient under guardianship, curatorship, deprived of liberty)
- 2- Lung scintigraphy and thoracic CT angiography evaluation to rule out pulmonary embolism
- 24- Patient on AME (state medical aid)
- 3- Women of childbearing potential
See the full eligibility criteria
- 1- Patients over 18 years ≤70 years
- 2- Social security affiliation
- 3- Good understanding of the French language
- 4- Written informed consent
- 5- Documented COVID-19 infection (PCR or CT scan) more than 3 months before inclusion
- 6- Long COVID suspicion with dyspnea (mMRC≥2 at inclusion)
- 7- DLCO<75% of predicted value less than 3 months old on the day of screening or to be obtained before Day 1 if older than 3 months.
- 1- Acute COVID-19 infection
- 22- Pregnant or breastfeeding women
- 23- Vulnerable populations (patient under guardianship, curatorship, deprived of liberty)
- 2- Lung scintigraphy and thoracic CT angiography evaluation to rule out pulmonary embolism
- 24- Patient on AME (state medical aid)
- 3- Women of childbearing potential
- 4- Myocardial infarction or stroke
- 5- Uncontrolled hypertension (>140/90 at inclusion in the study)
- 6- Proteinuria/creatinuria ratio > 50mg/mmol at baseline
- 8- History of malignant hypertension
- 10 - Previous osteonecrosis
- 14- Active cancer
- 11- History of Aneurysms and artery dissections
- 7- DFG<30 ml/min
- 9- Diagnosis of other pulmonary diseases known to impair DLCO (such as chronic obstructive pulmonary disease [COPD], idiopathic pulmonary fibrosis, interstitial lung diseases unrelated to COVID-19, or other significant chronic pulmonary conditions)
- 12- History of hemoptysis of any grade
- 13- History of congestive heart failure (NYHA class II-IV)
- 15- Known hypersensitivity to bevacizumab or any ingredient in its formulation, including non-medicinal ingredients, or a component of the container
- 16- Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanized antibodies.
- 17- History of Radiotherapy
- 18- History of bisphosphonates treatment
- 19- Surgery in 28 days before inclusion
- 20- Participation in another interventional study or being in the exclusion period at the end of a previous study
- 21- Patient unable or unwilling to comply with the follow-up schedule (at the investigator's discretion)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.